SoftBank-backed Vir Biotechnology costs IPO at low finish of… Vir Biotechnology priced its preliminary public providing (IPO) at $20 a share on Thursday, on the backside finish of expectations, a contemporary blow for SoftBank’s Imaginative and prescient Fund, proprietor of 21%… Expertiselearn extra cnbc.com
SoftBank-backed Vir Biotechnology costs IPO at low finish of…
Vir Biotechnology priced its preliminary public providing (IPO) at $20 a share on Thursday, on the backside finish of expectations, a contemporary blow for SoftBank’s Imaginative and prescient Fund, proprietor of 21%…
Expertiselearn extra